JAK inhibitors partially inhibit the activity of JAK enzymes and regulate intracellular signaling, consequently reducing the phosphorylation and activation of STAT proteins (Drożdżal et al., 2021), reducing the expression of IL-15, therefore JAK inhibitors have also been considered as a potential treatment for SJS/TEN (Xia et al., 2023). The gene discussed is SOAT1; the disease is Schwartz-Jampel syndrome.